Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pentaerithrityl Tetranitrate→

Pentaerithrityl Tetranitrate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
78-11-5
Molecular formula
C5H8N4O12
Molecular weight
316.14 g/mol
Drug class
Long-acting organic nitratenitric-oxide-donor antianginal vasodilator
Mechanism of action
Bioactivation of the organic nitrate releases nitric oxide or related nitrosating species, activating soluble guanylate cyclase and increasing cyclic GMP in vascular smooth muscle. Predominant venodilation reduces venous return and myocardial preload, lowering myocardial oxygen demand.
Indications / reported uses
  • Prevention and long-term management of angina pectoris with authorised oral formulations; it is not intended for immediate relief of an acute angina attack.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/6518 · https://pubchem.ncbi.nlm.nih.gov/compound/Pentaerythritol-tetranitrate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pentaerithrityl Tetranitrate Environmental Risk Assessment (ERA) (the Pentaerithrityl Tetranitrate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.